SCHEMBL6863817

SCHEMBL6863817

COc1ccc(C=O)cc1Cc1ccc(F)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.63
HPGD P15428 2/20 0.63
MEN1 O00255 1/20 0.63
POLB P06746 1/20 0.63
KMT2A Q03164 1/20 0.63
TSHR P16473 1/20 0.53
FDPS P14324 1/20 0.50
CYP1A2 P05177 2/20 0.49
RXFP1 Q9HBX9 1/20 0.49
AOX1 Q06278 1/20 0.49
MAOA P21397 1/20 0.48
MAOB P27338 1/20 0.48
NFE2L2 Q16236 1/20 0.47
NR3C1 P04150 1/20 0.46
NR3C2 P08235 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
TRIM24 O15164 1/20 0.45
ALDH5A1 P51649 1/20 0.45
ABAT P80404 1/20 0.45
TDP1 Q9NUW8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17521442 0.92 ALDH1A1 (0.60) ALDH1A1HPGDMEN1POLBKMT2A
SCHEMBL12635851 0.81 HDAC3 (0.54) ALDH1A1HPGDMEN1POLBKMT2A
SCHEMBL12636161 0.80 ALDH1A1 (0.51) ALDH1A1HPGDMEN1POLBKMT2A
SCHEMBL1353565 0.79 ALDH1A1 (0.64) ALDH1A1HPGDMEN1POLBKMT2A
SCHEMBL29957052 0.79 ALDH1A1 (0.66) ALDH1A1HPGDMEN1POLBKMT2A
SCHEMBL2432443 0.79 ALDH1A1 (0.66) ALDH1A1HPGDMEN1POLBKMT2A
SCHEMBL6582635 0.78 FDPS (0.61) ALDH1A1HPGDMEN1POLBKMT2A
SCHEMBL3890253 0.78 MEN1 (0.51) ALDH1A1MEN1KMT2ACYP1A2NPSR1
SCHEMBL7259956 0.77 FDPS (0.56) ALDH1A1HPGDMEN1POLBKMT2A
SCHEMBL24489075 0.76 ALDH1A1 (0.61) ALDH1A1HPGDMEN1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2655382-B1 ORGANOZINC COMPLEXES AND PROCESSES FOR MAKING AND USING THE SAME UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) 2022-09-28 EP disclosed
US-9273070-B2 Organozinc complexes and processes for making and using the same KNOCHEL PAUL (DE) 2016-03-01 US disclosed
US-9273070-B2 Organozinc complexes and processes for making and using the same KNOCHEL PAUL (DE) 2016-03-01 US disclosed
US-9273070-B2 Organozinc complexes and processes for making and using the same KNOCHEL PAUL (DE) 2016-03-01 US disclosed
US-20140031545-A1 ORGANOZINC COMPLEXES AND PROCESSES FOR MAKING AND USING THE SAME LUDWIG-MAXIMILIAN-UNIVERSITAT MUNCHEN (DE) 2014-01-30 US disclosed
US-20140031545-A1 ORGANOZINC COMPLEXES AND PROCESSES FOR MAKING AND USING THE SAME LUDWIG-MAXIMILIAN-UNIVERSITAT MUNCHEN (DE) 2014-01-30 US disclosed
US-20140031545-A1 ORGANOZINC COMPLEXES AND PROCESSES FOR MAKING AND USING THE SAME LUDWIG-MAXIMILIAN-UNIVERSITAT MUNCHEN (DE) 2014-01-30 US disclosed
EP-2655382-A1 ORGANOZINC COMPLEXES AND PROCESSES FOR MAKING AND USING THE SAME Ludwig-Maximilians-Universität München (DE) 2013-10-30 EP disclosed
WO-2012085168-A1 ORGANOZINC COMPLEXES AND PROCESSES FOR MAKING AND USING THE SAME LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) 2012-06-28 WO disclosed
EP-1286957-B1 DIPHENYLMETHANE DERIVATIVES BAYER HEALTHCARE AG (DE) 2004-11-03 EP disclosed
US-6803480-B2 THERAPEUTIC TREATMENT AND/OR PROPHYLAXIS OF ARTERIOSCLEROSIS AND HYPERCHOLESTEROLAEMIA BAYER AKTIENGESELLSCHAFT (DE) 2004-10-12 US disclosed
US-20030203898-A1 Therapeutic treatment and/or prophylaxis of arteriosclerosis and hypercholesterolaemia BAYER AKTIENGESELLSCHAFT (DE) 2003-10-30 US disclosed
EP-1286957-A1 DIPHENYLMETHANE DERIVATIVES Bayer Aktiengesellschaft (DE) 2003-03-05 EP disclosed
WO-2001090053-A1 DIPHENYLMETHANE DERIVATIVES BAYER AKTIENGESELLSCHAFT (DE) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031545-A1 ORGANOZINC COMPLEXES AND PROCESSES FOR MAKING AND USING THE SAME ODC1, AOC1, ADH1C ALDH1A1 185/4885HPGD 1461/4885MEN1 673/4885
US-20030203898-A1 Therapeutic treatment and/or prophylaxis of arteriosclerosis and hypercholesterolaemia APOB, HMGCR, PCSK9 ALDH1A1 1351/4885HPGD 1004/4885MEN1 1191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.